Kristina Burow
About Kristina Burow
Kristina Burow has served on Boundless Bio’s Board since June 2019 and is a Managing Director at ARCH Venture Partners (since November 2011), with prior roles at Novartis BioVenture Fund and the Genomics Institute of the Novartis Research Foundation; she holds a B.S. in Chemistry (UC Berkeley), an M.A. in Chemistry (Columbia), and an M.B.A. (University of Chicago) . She is independent and serves as a non-employee director under Exchange Act Rule 16b-3 for committee service .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| ARCH Venture Partners | Managing Director | Since Nov 2011 | Leads/participates in numerous life sciences investments |
| Novartis BioVenture Fund | Associate | Not disclosed | Early-stage investing experience |
| Genomics Institute of the Novartis Research Foundation | Early employee | Not disclosed | Scientific/operational foundation |
| Receptos, Inc. | Co-founder; Director until acquisition by Celgene (2015) | Until 2015 | Built to successful exit |
| Beam Therapeutics; Gossamer Bio; Metacrine; Unity Biotechnology; Vir Biotechnology | Director (prior) | Not disclosed | Governance roles across public biopharma |
External Roles
| Organization | Role | Public/Private | Tenure | Committees/Impact |
|---|---|---|---|---|
| Neumora Therapeutics, Inc. | Co-founder; Director | Public | Not disclosed | Not disclosed |
| Orbital Therapeutics Inc. | Co-founder; Director | Private | Not disclosed | Not disclosed |
| Metsera, Inc. | Director | Public | Not disclosed | Not disclosed |
| Scholar Rock Holding Corporation | Director | Public | Not disclosed | Not disclosed |
| Architect Therapeutics; Autobahn Therapeutics; Magnet Biomedicine; Mirador Therapeutics; Pretzel Therapeutics; ROME Therapeutics; Treeline Biosciences | Director | Private | Not disclosed | Not disclosed |
Board Governance
- Committee memberships: Compensation Committee (member); Nominating & Corporate Governance Committee (member); not a chair .
- Independence: Board determined all committee members are independent; Burow is a “non-employee director” for Compensation Committee purposes .
- Meetings/attendance (2024): Board met 5 times; Audit 4; Compensation 3; Nominating & Corporate Governance did not meet; each director attended ≥75% of applicable meetings .
- Compensation Committee practices: Uses independent consultant (Alpine Rewards); Committee assessed and found no consultant conflicts in 2024; oversees clawback policy implementation .
Fixed Compensation
| Component | Amount/Terms | Effective Date |
|---|---|---|
| Annual cash retainer (non-employee directors) | $40,000 | Mar 2024 |
| Additional retainer – Chair of Board/Lead Independent | $30,000 | Mar 2024 |
| Committee chair retainers | Audit $15,000; Compensation $10,000; Nominating & Corporate Governance $8,000 | Mar 2024 |
| Committee member retainers | Audit $7,500; Compensation $5,000; Nominating & Corporate Governance $4,000 | Mar 2024 |
| Initial Director Award (options) | 27,000 options; 3-year vest, monthly | Mar 2024 |
| Annual Director Award (options) | 13,500 options; 12-month vest, monthly; any remaining unvested vests at next annual meeting | Mar 2024 |
| Chair Award (for Board Chair) | 6,750 options; 12-month vest, monthly; catch-up at next annual meeting | Jun 20, 2024 |
| Increases to awards | Initial Award → 32,000; Annual Award → 16,000; Chair Award → 8,000 | Mar 27, 2025 |
| Change-in-control acceleration | Director awards vest upon change in control or death/disability | Ongoing |
| 2024 Director Compensation (BOLD) | Fees earned/paid ($) | Option awards ($) | All other comp ($) | Total ($) |
|---|---|---|---|---|
| Kristina Burow | 36,750 | 328,219 | — | 364,969 |
Performance Compensation
| Equity Award | Grant size | Strike price | Vesting | Performance Metrics | Notes |
|---|---|---|---|---|---|
| IPO-related option grant (2024) | 26,438 options to Burow | $16.00 per share | 3 years, equal monthly installments | None disclosed for directors (time-based) | Granted under 2024 Plan |
| Director equity program | Initial/Annual as above | Not disclosed (per award date FMV) | Monthly vesting schedules | None; time-based; CIC acceleration | Annual limits per 2024 Plan; Board can approve exceptions |
No performance metrics (e.g., revenue, EBITDA, TSR) are tied to non-employee director compensation; awards are time-based with specified vesting and change-in-control acceleration .
Other Directorships & Interlocks
- ARCH affiliation: Entities affiliated with ARCH Venture Partners own 2,694,095 BOLD shares (12.1%); Burow is an ARCH Managing Director and an Investment Committee Member for AVP X LLC, and may be deemed to share power over AVF X Overage’s shares; she owns interests in AVF IX and AVF IX Overage but does not have voting or dispositive power over shares held by those funds and disclaims beneficial ownership except to pecuniary interest .
- Pre-IPO governance agreements: Voting Agreement (Aug 2018; amended Apr 2023) designated certain directors (including Burow); terminated at IPO close . Investors’ Rights Agreement provided registration rights that survive until four years post-IPO .
- Series C financing (Apr–May 2023): Related parties acquired preferred shares converted at IPO; ARCH entities participated (14,285,713 Series C shares pre-conversion); Burow’s ARCH affiliation noted .
Expertise & Qualifications
- Education: B.S. Chemistry (UC Berkeley), M.A. Chemistry (Columbia University), M.B.A. (University of Chicago) .
- Domain expertise: Extensive board service across clinical-stage biotech; led/co-led numerous ARCH investments (Erasca, Aledade, Kythera, Kura Oncology, Ikaria) .
- Board qualifications: Life sciences investment and governance experience; rationale for BOLD Board selection explicitly cited .
Equity Ownership
| Holder | Shares Beneficially Owned (No.) | % of Outstanding | Composition |
|---|---|---|---|
| Kristina Burow | 2,704,376 | 12.1% (of 22,300,043 outstanding) | 10,281 options exercisable within 60 days + ARCH-affiliated shares (see breakdown) |
| ARCH-affiliated breakdown (linked to Burow’s deemed beneficial ownership) | 2,694,095 total | 12.1% of outstanding | AVF IX: 683,759; AVF IX Overage: 828,570; AVF X Overage: 1,181,766 |
- Ownership notes: Burow disclaims beneficial ownership of ARCH fund shares except to the extent of pecuniary interest; no pledge or hedging disclosures specific to Burow were provided .
- Shares outstanding reference date: 22,300,043 (as of April 25, 2025) .
Insider Trades and Section 16 Compliance
| Item | Status/Notes |
|---|---|
| Section 16(a) reporting (2024) | Company believes all directors/officers/10% holders met timely filing requirements in 2024 |
Governance Assessment
- Strengths: Independent director with deep biotech investing and board experience; active on Compensation and Nominating & Corporate Governance committees; attendance ≥75% in 2024; use of independent compensation consultant (no conflicts) supports process integrity .
- Alignment: Significant economic exposure via ARCH-affiliated holdings and personal options; director equity awards vest over time with change-in-control acceleration, aligning interests but without performance metrics typical for directors .
- Potential conflicts/RED FLAGS: ARCH is a major stockholder (12.1%); Burow’s ARCH leadership and investment committee role could present perceived conflicts on matters affecting large holders (mitigated by disclaimers and independence determinations) . The Compensation Committee operated during years when executive options were repriced (June 2023; August 2024), a practice often scrutinized by investors; committee oversight and rationale should be monitored for pay-for-performance alignment . The Nominating & Corporate Governance Committee did not meet in 2024, which may raise questions about governance cadence and oversight of ESG/corporate governance matters .
- Protective provisions: Standard Delaware indemnification agreements and D&O insurance in place; investors’ registration rights persist post-IPO for four years, which can affect secondary liquidity dynamics .
Overall signal: Deep sector expertise and large-holder alignment are positives, but ARCH interlocks and the history of executive option repricing under the Compensation Committee warrant continued monitoring by investors for conflicts and pay discipline .